Daily Brief Thematic (Sector/Industry): China Healthcare Weekly (Jan.27) - Surgical Robots New Policy and more

In today’s briefing:

China Healthcare Weekly (Jan.27) – Surgical Robots New Policy, COVID-19 Update, Policy Vacuum Period
Japan Weekly | Bullish Markets, Suzuki, Shin-Etsu
Sands China Ltd: Breakthrough to Profitability Is First Forerunner of Macau Recovery Cycle

China Healthcare Weekly (Jan.27) – Surgical Robots New Policy, COVID-19 Update, Policy Vacuum Period

New policy was released to support the development of surgical robots in China, which would be short-term catalyst for related companies, but it may not bring high profits.
In fact, since March, it may not be appropriate for healthcare companies to use the COVID-19 as a reason if their performance in the following months is not as expected.
Before DRGs/DIP policy becomes very “lethal”, there is a “policy vacuum period” in the next two or three years, which is a good opportunity to go long in China healthcare.

Global markets continued positive momentum on peaking in global inflation and expectations that the rate hike cycle is approaching its end
There is a slew of economic data next week and some major US tech company results announcements. Japanese earnings announcements get into full swing
Suzuki was the start performer last week as investors cheered the company’s new mid-term strategy and decarbonization plans

Revenues for 2022 just missed forecast, but enough to put the Macau market share leader over the top and into positive profit territory.
Indications during CNY show average bet of US$101 per hand clearly put premium mass play back in action with mass segment spurts evident during the holiday.
CNY arrivals hit 90,000 on Tuesday, best in three years. Current run rate now reaching 40% of pre-covid baseline 2019.

💡 Before it’s here, it’s on Smartkarma

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network